Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery

Inclusion Criteria:

pre-operative

1. Subjects who are able to provide written informed consent prior to participating inthe clinical investigation.

2. Subjects who are ≥ 18 years old.

3. Subjects who are able to comply with the follow-up or other study requirements.

4. Subjects wo are planned for elective surgery including a trepanation to reach thesubdural infratentorial space (with lower limit of incision defined as the loweredge of C2) in whom a dural incision will be closed.

5. Female subjects of child bearing potential must agree to use a form of contraceptionfrom the time of signing the informed consent form through 90 days post-surgery.

intra-operative

1. Subjects with surgical wound classification Class I/Clean.

2. Subjects with minimally 5 mm of dural space surrounding dural opening.

Exclusion Criteria:

pre-operative

1. Female subjects who are pregnant or breastfeeding.

2. Subjects with an assumed impaired coagulation due to medication or otherwise.

3. Subjects suspected of an infection requiring antibiotics.

4. Subjects with any type of dural diseases in planned dural closure area.

5. Subjects requiring re-opening of planned surgical area within 90 days after surgery.

6. Subjects with a known allergy to any of the components (Lactide-Caprolactoneco-polyester; Butanediol-BDI co-polyurethane; Polyethylene glycol SuccinimidylGluterate; Disodium hydrogen phosphate or D&C Green No 6) of LIQOSEAL®.

7. Subjects who previously received a LIQOSEAL®.

8. Subjects who previously participated in this study or any investigational drug ordevice study within 30 days of screening.

9. Subjects with a presence of hydrocephalus.

10. Subjects with contra-indication to MRI [cardiac pacemaker or defibrillator, severeclaustrophobia, injured by a metallic object that was not removed, cochlear (ear)implants, metallic implants [e.g. knee replacement].

intra-operative

1. Subjects in whom elevation of PEEP has a potential detrimental effect.

2. Subjects who will require a CSF drain, electrodes or other devices passing the durallayer or extra to intracranial bypass surgery.

3. Subjects who have primary closure of the dura mater with synthetic, nonautologous orautologous material other than galea.

4. Subjects in whom no intra-operative CSF leakage is present after primary closure ofthe dura mater with elevation of PEEP.

5. Subjects who after primary closure (including galea, if applicable) of the duramater have a gap > 3 mm.

6. Subjects whom dural opening size including 5 mm margin exceeds patch size (8 x 8cm).